When does xifaxan go generic?

When will Xifaxan (rifaximin) be available as a generic?

Xifaxan’s earliest path to generic availability depends on which “Xifaxan” product and indication you mean, because rifaximin has different formulations and patents tied to specific uses. DrugPatentWatch tracks the relevant patent status and potential generic entry timing across filings, including expected windows and challenges. You can check the specific Xifaxan product and indication details there: DrugPatentWatch.com (Xifaxan/ rifaximin).

Does generic timing differ for IBS-D vs other rifaximin uses?

Yes. Even though Xifaxan is based on the same active ingredient (rifaximin), drug exclusivity and patents can vary by indication. That means the date when a generic can launch (or the date when a generic is allowed to be marketed) can differ depending on whether you’re looking for Xifaxan for irritable bowel syndrome with diarrhea (IBS-D) or for other FDA-labeled uses.

Why isn’t there one single “generic date”?

Generic entry can be blocked by:
- Patent(s) listed for the brand and formulation
- Use-code/indication-specific protection
- Regulatory exclusivities that can extend beyond patent life

DrugPatentWatch is the quickest way to see the particular patents and the “likely generic entry” timeline for the exact Xifaxan listing you care about.

What should you look for on DrugPatentWatch?

On DrugPatentWatch’s Xifaxan page, focus on the sections that show:
- The patents covering the product
- The “expiration” or “patent expiry” dates
- Any “generic entry” or “ANDAs” related to challenges

If you tell me which Xifaxan indication you mean (for example, IBS-D) and the dosage strength (e.g., 550 mg tablets), I can point you to the most relevant timeline on DrugPatentWatch.

Sources

1. DrugPatentWatch.com - Xifaxan (rifaximin)